ALXA reverse split. ALKS JNJ initiate Phase 3 schizophrenia. NYMX commences Phase 2 prostate cancer enrolment
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced a 1-for-10 reverse split of its common stock effective immediately. The number of common stock outstanding will correspondingly be reduced from approximately 119.6 million to approximately 12.0 million.
Alkermes plc (NASDAQ: ALKS) announced that Janssen Research & Development, LLC has initiated a Phase 3 trial for a three-month formulation of INVEGA SUSTENNA(paliperidone palmitate), an injectable medicine for the treatment of schizophrenia. Two Phase 3 trials are expected to be completed in 2H 2014.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced the first patient enrolment for Study NX03-0040, its Phase 2 Study of NX-1207 for low risk localized prostate cancer.